RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year. Each of these eye disorders was being targeted by RegeneRx prior to entering into the joint venture.

Earlier clinical trials with RGN-259 (thymosin beta 4 ophthalmic solution) have demonstrated the drug candidate's ability to significantly improve both signs and symptoms of DES and identified co-primary endpoints to be targeted in the DES trials. Results of a small physician-sponsored phase 2 clinical trial in patients with severe dry eye were recently published in Cornea (2015 May;34(5):491-496) demonstrating statistically significant improvements in patients' signs and symptoms. Positive results with RGN-259 have also been seen in patients with chronic neurotrophic keratopathy, a degenerative disease of the corneal epithelium resulting from impaired corneal innervation that may cause ulceration and perforation of the cornea.

Ora is a recognized leader in ophthalmic product development and has developed a Controlled Adverse Environment (CAE®) model for dry eye allowing rapid recruitment, treatment and evaluation of patients with DES. Ora has significant experience with RGN-259 having previously conducted a 72-patient phase 2 dry eye trial with the drug candidate on behalf of RegeneRx.


RegeneRx Biopharmaceuticals, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New biomarkers in the eyes could unlock the key to management of diabetic retinopathy